Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals

MT1and MT2Melatonin Receptors: A Therapeutic Perspective

(2016) Jiabei Liu et al.   Annual Review of Pharmacology and Toxicology

Absolute Bioavailability of Tasimelteon

(2015) Rosarelis Torres et al.   AMERICAN JOURNAL OF THERAPEUTICS

Safety profile of tasimelteon, a melatonin MT1and MT2receptor agonist: pooled safety analyses from six clinical studies

(2015) Damien Leger et al.   Expert Opinion On Drug Safety

Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment

(2015) Rosarelis Torres et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist

(2015) Brian W. Ogilvie et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015

(2015) R. Robert Auger et al.   Journal of Clinical Sleep Medicine

Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials

(2015) Steven W Lockley et al.   LANCET

Entraining the free-running circadian clocks of blind people

(2015) Charmane Eastman   LANCET

Tasimelteon: A selective and unique receptor binding profile

(2015) Christian Lavedan et al.   NEUROPHARMACOLOGY

Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients

(2014) Stephen M. Stahl   CNS SPECTRUMS

Blacks (African Americans) Have Shorter Free-Running Circadian Periods Than Whites (Caucasian Americans)

(2012) Charmane I. Eastman et al.   CHRONOBIOLOGY INTERNATIONAL

Human Phase Response Curves to Three Days of Daily Melatonin: 0.5 mgVersus3.0 mg

(2010) Helen J. Burgess et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Human Tau in an Ultradian Light-Dark Cycle

(2008) Helen J. Burgess et al.   JOURNAL OF BIOLOGICAL RHYTHMS

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials

(2008) Shantha MW Rajaratnam et al.   LANCET